1. Editorial

   • J. M. Aiache

   EditorialNotes Pages: 85 - 85

2. Professor Giorgio Segre

   • A. Benakis

   EditorialNotes Pages: 86 - 86

3. Development of midazolam sublingual tablets: in vitro study

   • P. Odou
   • C. Barthelemy
   • H. Robert

   OriginalPaper Pages: 87 - 91

4. Influence of shaking and surfactants on the release of bsa from plga microspheres

   • R. M. Hernádez
   • M. Igartua
   • J. L. Pedraz

   OriginalPaper Pages: 92 - 96

5. Gastric juice as a dissolution medium: Surface tension and pH

   • M. Efentakis
   • J. B. Dressman

   OriginalPaper Pages: 97 - 102

6. Effect of PEG 4000 on the dissolution rate of naproxen

   • I. Vélaz
   • M. Sánchez
   • M. C. Martínez-Ohárriz

   OriginalPaper Pages: 103 - 108

7. Dissolution kinetics for coprecipitates of diflunisal with PVP K30

   • C. Rodríguez-Espinosa
   • M. C. Martínez-Ohárriz
   • M. Sánchez

   OriginalPaper Pages: 109 - 112

8. Preparation and dissolution rate of gliquidone-PVP K30 solid dispersions

   • P. Martnez
   • M. M. Goñi
   • C. Martínez-Ohárriz

   OriginalPaper Pages: 113 - 117

9. Pharmacokinetic examination of antipyrine passage through the placenta and the small intestine in rats

   • F. Štaud
   • Z. Fendrich
   • O. Jindrová

   OriginalPaper Pages: 118 - 124

10. Distribution of deramciclane (EGIS-3886) in rat brain regions

    • K. Magyar
    • J. Lengyel
    • G. Grézal

    OriginalPaper Pages: 125 - 131

11. In vitro study of the binding of doxorubicin to heart

    • L. Álvarez-Cedrón
    • F. G. López
    • J. M. Lanao

    OriginalPaper Pages: 132 - 136

12. Catechol is the major product of salicylate hydroxylation in 1-methyl-4-phenylpyridinium ion treated rats

    • E. Sam
    • S. Sarre
    • N. Verbeke

    OriginalPaper Pages: 137 - 142

13. Pharmacokinetic parameters of netilmicin and protective effect of piperacillin regarding nephrotoxicity caused by netilmicin

    • M. Santos Navarro
    • A. Zarzuelo Castañeda
    • J. M. Lanao

    OriginalPaper Pages: 143 - 147

14. Robust methods in bioequivalence assay; Preliminary results

    • A. V. Niselman
    • M. Garcia Ben
    • M. C. Rubio

    OriginalPaper Pages: 148 - 152

15. Average parameters as a trend to reduce the residual variability in bioequivalence trials

    • P. Fagiolino
    • M. Vazquez

    OriginalPaper Pages: 153 - 159

16. Average parameters in bioavailability studies: an application to slow-release amitriptyline formulation

    • P. Fagiolino
    • M. Vázquez
    • E. Beyssac

    OriginalPaper Pages: 160 - 165

17. Which bioequivalence study for a racemic drug? Application to milnacipran

    • D. Deprez
    • D. Chassard
    • C. Puozzo

    OriginalPaper Pages: 166 - 171

18. Comparative bioavailability of two oral formulations of ipriflavone in healthy volunteers at steady-state. Evaluation of two different dosage schemes

    • D. Acerbi
    • G. Poli
    • P. Ventura

    OriginalPaper Pages: 172 - 177

19. Relative bioavailability of different oral sustained release oxprenolol tablets

    • S. E. Leucuta
    • M. Follidis
    • A. Mocan

    OriginalPaper Pages: 178 - 184

20. Comparative bioavailability study of codeine and ibuprofen after administration of the two products alone or in association to 24 healthy volunteers

    • J P Laneury
    • P. Duchene
    • P. Molinier

    OriginalPaper Pages: 185 - 189

21. Biopharmaceutical evaluation of time-controlled press-coated tablets containing polymers to adjust drug release

    • M. Halsas
    • P. Ervasti
    • M. Marvola

    OriginalPaper Pages: 190 - 196

22. Food effect on the oral bioavailability of Manidipine: single dose, randomized, crossover study in healthy male subjects

    • D. Rosillon
    • A. Stockis
    • B. Jeanbaptiste

    OriginalPaper Pages: 197 - 202

23. Is one paracetamol suppository of 1000 mg bioequivalent with two suppositories of 500 mg

    • T. Närvänen
    • M. Halsas
    • M. Marvola

    OriginalPaper Pages: 203 - 206

24. LIMS: from theory to practice

    • J-M. Cardot
    • T. Hulot
    • A. Stockis

    OriginalPaper Pages: 207 - 212

25. Bioavailability of the iron formulated as natural ferric protein (TM/FMOA) and natural ferric protein + folic acid (TM/FMOA+FOL)

    • E González-Peñas
    • P Martinez
    • P Coronel

    OriginalPaper Pages: 213 - 217

26. Amiloride pharmacokinetics in rat

    • G. Segre
    • D. Cerretani
    • G. Giorgi

    OriginalPaper Pages: 218 - 222

27. ¹⁴C-NaVP and¹⁴C-PEV repeated dose study in rat pharmacokinetic study in rats after repeated oral administrations of¹⁴C-valproic acid sodium salt and¹⁴C-valproic acid pivaloyl oxymethyl ester

    • M. Bertolino
    • D. Acerbi
    • G. Zanolo

    OriginalPaper Pages: 223 - 229

28. Pharmacokinetic study in rats after single intravenous and oral administrations of [¹⁴C]-ITF-296

    • C. Giachetti
    • M. Bertolino
    • G. Zanolo

    OriginalPaper Pages: 230 - 238

29. Pharmacokinetic study in dogs and monkeys after single intravenous and oral administrations of [¹⁴C]-ITF-296

    • C. Giachetti
    • M. Bertolino
    • G. Zanolo

    OriginalPaper Pages: 239 - 250

30. Pharmacokinetics of Camonagrel in experimental animal: rat, rabbit and dog

    • C. Albet
    • A. Pérez J. A.
    • J. A. Ortiz

    OriginalPaper Pages: 251 - 254

31. Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients

    • R. Boulieu
    • B. Lehmann
    • D. Morlet

    OriginalPaper Pages: 255 - 258

32. Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias

    • V. L. Lanchote
    • E. J. Cesarino
    • S. R. C. J. Santos

    OriginalPaper Pages: 259 - 266

33. Technetium-99m labelling of human immunoglobulin and preliminary clinical evaluation in tumour patients

    • A. D. Varvarigou
    • S. C. Archimandritis
    • P. Kostamis

    OriginalPaper Pages: 267 - 272

34. Pharmacokinetics of milnacipran in liver impairment

    • C. Puozzo
    • H. Albin
    • M. Amouretti

    OriginalPaper Pages: 273 - 279

35. Pharmacokinetics of milnacipran in renal impairment

    • C. Puozzo
    • N. Pozet
    • P. Zech P

    OriginalPaper Pages: 280 - 286

36. Distribution of fenofibric acid in lipoprotein fractions of patients

    • M. Nobilis
    • J. Kvetina
    • J. Vlcek

    OriginalPaper Pages: 287 - 294

37. Evaluation of a bayesian pharmacokinetic program for phenytoin concentration predictions in outpatient population

    • J. M. Gaulier
    • R. Boulieu
    • Mauguiere

    OriginalPaper Pages: 295 - 300

38. OKT3 monitoring in the treatment of steroid-resistant acute rejection of hepatotransplant recipients

    • P. Brusa
    • R. Casullo
    • M. Salizzoni

    OriginalPaper Pages: 301 - 306

39. Surfactant effects on the in vitro percutaneous absorption of diclofenac sodium

    • A. Arellano
    • S. Santoyo
    • P. Ygartua

    OriginalPaper Pages: 307 - 312

40. An improved everted gut sac as a simple and accurate technique to measure paracellular transport across the small intestine

    • L. Barthe
    • J. F. Woodley
    • G. Houin

    OriginalPaper Pages: 313 - 323

41. Chromatographic investigation and computer simulation of L-deprenyl metabolism

    • ZS. Tarjányi
    • H. Kalász
    • S. Fürst

    OriginalPaper Pages: 324 - 328

42. Determination of lansoprazole in biological fluids and pharmaceutical dosage by HPLC

    • A. Avgerinos
    • Th. Karidas
    • S. Axarlis

    OriginalPaper Pages: 329 - 332

43. Acetaminophen presystemic biotransformation vs bioavailability in therapeutical dosage range

    • A. G. Goicoechea
    • J. L. Vila-Jato

    OriginalPaper Pages: 333 - 338

44. Use of the repeated cross-over design in assessing bioequivalence: (within and between subjects variability — Schuirmann Confidence Intervals estimation)

    • Y. Le Roux
    • C. Guimart
    • M. Tenenhaus

    OriginalPaper Pages: 339 - 345

45. Biological and clinical study kinetics of biodegrading apatite-collagen implant for substituting bone tissue defects

    • S. D. Litvinov

    OriginalPaper Pages: 346 - 349

46. Treatment of lactose intolerance with exogenous beta-D-galactosidase in pellet form

    • K. Xenos
    • S. Kyroudis
    • P. Papastathopoulos

    OriginalPaper Pages: 350 - 355